Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells

Biochemical Pharmacology

Volumn 69, Issue 2, 2005, Pages 267-275

  Ahlström, Mikael ^a   Pekkinen, Minna ^a   Huttunen, Minna ^a   Lamberg Allardt, Christel ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

cAMP; Dexamethasone; Glucocorticoids; Osteoblast; Osteosarcoma; Phosphodiesterase

Indexed keywords

CILOSTAMIDE; CYCLIC AMP PHOSPHODIESTERASE; CYCLIC GMP; DEXAMETHASONE; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE IV; ROLIPRAM; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

ARTICLE; CELL ACTIVITY; CELL FREE SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; HYDROLYSIS; OSTEOBLAST; OSTEOSARCOMA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BONE TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; OSTEOSARCOMA; PHYSIOLOGY; TUMOR CELL LINE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BONE NEOPLASMS; CELL LINE, TUMOR; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; OSTEOSARCOMA; PHOSPHODIESTERASE INHIBITORS;

EID: 13844272554     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.09.012     Document Type: Article

References (43)

1. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994;9:1097-105.
2. Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol 1997;137:209-17.
3. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998;244:271-92.
4. Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001;29:498-505.
5. Manelli F. Giustina a glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 2000;11:79-85.
6. Jilka RL, Weinsrein RS, Bellido T, Robertson P, Parfitt AM, Manolagas SC. J Clin Invest 1999;104:439-46.
7. McCarthy TL, Centrella M, Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1989;124:1247-53.
8. McCarthy TL, Centrella M, Raisz LG, Canalis E. Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1991;128:2895-900.
9. McCarthy TL, Ji C, Chen Y, Kim K, Centrella M. Time- and dose-related interactions between glucocorticoid and cyclic adenosine 3′5′- monophosphate on CCAAT/enhancer-binding protein-dependent insulin-like growth factor I expression by osteoblasts. Endocrinology 2000;141:127-37.
10. Noda M, Yoon K, Rodan GA. Cyclic AMP-mediated stabilization of osteocalcin mRNA in rat osteoblast-like cells treated with parathyroid hormone. J Biol Chem 1988;263:18574-7.
11. Lajeunesse D, Kiebzak GM, Frondoza C, Sacktor B. Regulation of osteocalcin secretion by human primary bone cells and by the human osteosarcoma cell line MG-63. Bone Miner 1991;14:237-50.
12. Partridge NC, Bloch SR, Pearman AT. Signal transduction pathways mediating parathyroid hormone regulation of osteoblastic gene expression. J Cell Biochem 1994;55:321-7.
13. Conti M, Jin S-LC. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 1999;63:1-38.
14. Mehats C, Andersen CB, Filopanti M, Jin S-LC, Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 2002;13:29-35.
15. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003;370:1-18.
16. Thompson WJ, Appleman MM. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971;10:311-6.
17. Frandsen EK, Krishna G. A simple ultrasensitive method for the assay of cyclic AMP and cyclic GMP in tissues. Life Sci 1976;18:529-41.
18. Ahlström M, Lamberg-Allardt C. Inactivation of atrial natriuretic factor-stimulated cyclic guanosine 3′5′-monophosphate (cGMP) in UMR-106 osteoblast-like cells. Biochem pharmacol 2000;59:1133-9.
19. Sakakibara H, Conti M, Weiner RI. Role of phosphodiesterases in the regulation of gonadotropin-releasing hormone secretion in GT1 cells. Neuroendocrinology 1998;68:365-73.
20. Kuthe A, Wiedenroth A, Magert HJ, Uckert S, Forssmann WG, Stief CG, et al. Expression of different phosphodiesterase genes in human cavernous smooth muscle. J Urol 2001;165:280-3.
21. Ekholm D, Hemmer B, Gao G, Vergelli M, Martin R, Manganiello V. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. J Immunol 1997;159:1520-9.
22. Leroy M-J, Mehats C, Duc-Goiran P, Tanguy G, Robert B, Dallot E, et al. Effect of pregnancy on PDE4 cAMP-specific phosphodiesterase messenger ribonucleic acid expression in human myometrium. Cell Signal 1999;11:31-7.
23. Torphy TJ, Zhou HL, Foley JJ, Sarau HM, Manning CD, Barnette MS. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. J Biol Chem 1995;270:23598-604.
24. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 1999;56:170-4.
25. Erdogan S, Houslay MD. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem J 1997;321:165-75.
26. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PJ. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 1996;118:1945-58.
27. Grayeli AB, Sterkers O, Roulleau P, Elbaz P, Ferrary E, Silve C. Parathyroid hormone-parathyroid hormone-related peptide receptor expression and function in otosclerosis. Am J Physiol 1999;277: E1005-12.
28. Fuhrmann M, Jahn HU, Seybold J, Neurohr C, Barnes PJ, Hippenstiel S, et al. Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Resp Cell Mol Biol 1999;20:292-302.
29. Rena G, Begg F, Ross A, MacKenzie C, McPhee I, Campbell L, et al. Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10. Mol Pharmacol 2001;59:996-1011.
30. Huston E, Lumb S, Russell A, Catterall C, Ross AH, Steele MR, et al. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem J 1997;328:549-58.
31. Perry MJ, Higgs GA. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr Opin Chem Biol 1998;2:474-81.
32. Ahlström M, Lamberg-Allardt C. Rapid protein kinase A-mediated activation of cyclic AMP-phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like cells. J Bone Miner Res 1997;12:172-8.
33. Mori K, Shioi A, Jono S, Nishizawa Y, Morii H. Dexamethasone enhances in vitro vascular calcification by promoting osteoblastic differentiation of vacular smooth muscle cells. Arterioscler Thromb Vascul Biol 1999;19:2112-8.
34. Yang RS, Liu TK, Lin-Shiau SY Increased bone growth by local prostaglandin E2 in rats. Calcif Tissue Int 1993;52:57-61.
35. Miyamoto K, Waki Y, Horita T, Kasugai S, Ohya K. Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem Pharmacol 1997;54:613-7.
36. Waki Y, Horita T, Miyamoto K, Ohya K, Kasugai S. Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclast-genesis in culture and its therapeutic effects in rat osteopenia models. Jpn J Pharmacol 1999;79:477-83.
37. Miyamoto K, Suzuki H, Yamamoto S, Saitoh Y, Ochiai E, Moritani S, et al. E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture. J Bone Miner Res 2003;18:1471-7.
38. Kinoshita T, Kobayashi S, Ebara S, Yoshimura Y, Horiuchi H, Tsutsumimoto T, et al. Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone 2000;27:811-7.
39. Horiuchi H, Saito N, Kinoshita T, Wakabayashi S, Tsutsumimoto T, Takaoka K. Enhancement of bone morphogenetic protein-2-induced new bone formation in mice by the phosphodiesterase inhibitor pentoxifylline. Bone 2001;28:290-4.
40. Rawadi G, Ferrer C, Spinella-Jaegle S, Roman-Roman S, Bouali Y, Baron R. 1-(5-Oxohexyl)-3,7-dimethylxanthine, a phosphodiesterase inhibitor, activates MAPK cascades and promotes osteoblast differentiation by a mechanism independent of PKA activation (pentoxifylline promotes osteoblast differentiation). Endocrinology 2001;142: 4673-82.
41. Rizzoli R, von Tscharner V, Fleisch H. Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells. Biochem J 1986;237:447-54.
42. Wong MM, Rao LG, Ly H, Hamilton L, Tong J, Sturtridge W, et al. Long-term effects of physiologic concentrations of dexamethasone on human bone-derived cells. J Bone Miner Res 1990;5:803-13.
43. Titus L, Jackson E, Nanes MS, Rubin JE, Catherwood BD. 1,25-dihydroxyvitamin D reduces parathyroid hormone receptor number in ROS 17/2.8 cells and prevents the glucocorticoid-induced increase in these receptors: relationship to adenylate cyclase activation. J Bone Miner Res 1991;6:631-7.